Skip to main content
Clinical Trials/NCT06431555
NCT06431555
Recruiting
Not Applicable

Magnetic Resonance Lung Function Imaging Study of Pulmonary Fibrosis Combined With Emphysema Syndrome

Beijing Chao Yang Hospital1 site in 1 country55 target enrollmentJanuary 10, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Using Functional Lung MRI to Explore Pulmonary Perfusion Changes in Patients With Pulmonary Fibrosis and Emphysema Syndrome
Sponsor
Beijing Chao Yang Hospital
Enrollment
55
Locations
1
Primary Endpoint
perfusion defect percentage
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This study intends to use magnetic resonance pulmonary function imaging technology to explore imaging markers for early diagnosis of patients with CPFE. Through baseline, 6-month and 12-month follow-up examinations, the changes in magnetic resonance pulmonary function in patients with CPFE and their correlation with disease progression were explored.

Registry
clinicaltrials.gov
Start Date
January 10, 2024
End Date
June 30, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Beijing Chao Yang Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • (1) Chest HRCT shows emphysema mainly distributed in the upper lung field, manifesting as wallless or thin-walled (wall thickness \<1 mm) low-transmittance areas with clear boundaries with normal tissue, or multiple bullae (diameter \> 1 cm), and the emphysema area/total lung volume is ≥10%; (2) interstitial pulmonary fibrosis mainly distributed in the lower lung field and subpleura, manifesting as honeycomb shadow or grid shadow, and the lung structure is destroyed , may be accompanied by traction bronchiectasis, ground glass opacities and consolidation opacities.

Exclusion Criteria

  • (1) Refusal to sign the informed consent form; (2) MRI contraindications (implanted pacemaker/defibrillator, claustrophobia, or any clinical condition that prohibits longer MRI examinations).

Outcomes

Primary Outcomes

perfusion defect percentage

Time Frame: 12 months

Calculate MRI lung perfusion defect as a percentage of the whole lung

Study Sites (1)

Loading locations...

Similar Trials